A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2018
At a glance
- Drugs Ofatumumab (Primary) ; Cyclophosphamide; Fludarabine
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 06 Jan 2018 Planned End Date changed from 31 Dec 2017 to 31 Dec 2019.
- 06 Jan 2018 Planned primary completion date changed from 31 Dec 2017 to 31 Dec 2019.
- 03 Nov 2017 Planned primary completion date changed from 31 Oct 2017 to 31 Dec 2017.